Illumina (NASDAQ:ILMN) Price Target Raised to $210.00

Posted by Brenda Bartman on Nov 2nd, 2026

Illumina (NASDAQ:ILMN – Get Free Report) had its price objective boosted by Citigroup from $113.00 to $210.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has a “sell” rating on the life sciences company’s stock. Citigroup‘s price target would suggest a potential downside of 8.06% from the stock’s previous close.

ILMN has been the topic of several other reports. Piper Sandler upped their price target on shares of Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, September 28th. Evercore reaffirmed an “underperform” rating on shares of Illumina in a research note on Friday. Guggenheim increased their price target on Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Barclays boosted their price objective on Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a report on Wednesday, October 7th. Finally, JPMorgan Chase & Co. dropped their price objective on Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a report on Friday. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $244.24.

View Our Latest Stock Report on Illumina

Illumina Trading Down 3.2%

Shares of Illumina stock traded down $7.58 on Monday, reaching $228.41. The company had a trading volume of 1,632,602 shares, compared to its average volume of 2,175,053. The firm has a market cap of $34.49 billion, a price-to-earnings ratio of 39.37, a P/E/G ratio of 3.30 and a beta of 1.46. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05. The firm’s 50-day moving average price is $249.30 and its two-hundred day moving average price is $176.18. Illumina has a 1 year low of $112.65 and a 1 year high of $309.35.

Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The company had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. Illumina’s revenue was up 4.2% on a year-over-year basis. During the same period last year, the company earned $1.34 earnings per share. As a group, research analysts predict that Illumina will post 5.43 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders sold 2,061,235 shares of company stock valued at $436,356,102. 2.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Illumina

Several large investors have recently made changes to their positions in ILMN. Signature Equity Partners LLC boosted its stake in Illumina by 246.5% during the third quarter. Signature Equity Partners LLC now owns 149 shares of the life sciences company’s stock worth $41,000 after buying an additional 106 shares during the last quarter. Fiduciary Financial Advisors acquired a new position in shares of Illumina during the 2nd quarter valued at about $26,000. MCF Advisors LLC grew its holdings in shares of Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 100 shares during the period. Keating Financial Advisory Services Inc. purchased a new stake in shares of Illumina in the second quarter valued at about $32,000. Finally, Rakuten Securities Inc. acquired a new stake in Illumina during the second quarter worth about $33,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Illumina reported third-quarter adjusted earnings above expectations and raised its full-year revenue and earnings guidance. Healthy margins, solid free cash flow and continued clinical sequencing demand provided fundamental support. Illumina (ILMN) Stock Falls After Q3 Results Lift Guidance
Positive Sentiment: Strong demand for clinical sequencing and robust placements of the NovaSeq X platform are supporting potential margin and earnings expansion. New offerings, including the BioInsight software suite, could add to future growth. The top 5 analyst questions from Illumina’s Q3 earnings call
Positive Sentiment: Analyst coverage continues to highlight Illumina’s long-term growth potential, including the contribution of international revenue and the company’s exposure to expanding genomic-testing markets. Why Illumina (ILMN) is a Top Growth Stock for the Long-Term
Neutral Sentiment: International revenue trends remain an important variable for Wall Street forecasts. Investors are assessing whether overseas growth can offset uneven demand across Illumina’s end markets. Don’t Overlook Illumina International Revenue Trends While Assessing the Stock
Neutral Sentiment: A report projects the global forensic technologies and services market will grow substantially through 2030, potentially creating longer-term opportunities for companies involved in advanced DNA sequencing and AI-enabled forensics. Forensic Technologies and Services Global Strategic Business Report
Negative Sentiment: The market reaction was negative because investors viewed Illumina’s valuation—near 40 times trailing earnings—as demanding, even after the guidance increase. The results suggested a more measured growth profile than the valuation may imply. What Sent Illumina Stock Lower?
Negative Sentiment: Research and applied markets remain weak, partially offsetting clinical momentum. Analyst downgrades, a lower JPMorgan price expectation and the stock’s move below its 50-day moving average added further pressure. JPMorgan Lowered Expectations for Illumina Stock

About Illumina

(Get Free Report)

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.